ORTIN GLOBAL per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
−₹1.12−₹0.91−₹1.04−₹9.89−₹0.08
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−₹1.12−₹0.91−₹1.04−₹9.89−₹0.08
₹1.52₹1.52₹2.43₹3.47₹13.36
₹0.09₹0.12₹0.42₹2.60₹7.40
—−₹0.69−₹0.50−₹4.52−₹0.27
−₹0.69−₹0.69−₹0.51−₹4.52−₹0.27
0.80.80.80.80.8
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ORTINGLOBE₹12.41

ORTIN GLOBAL LIMITED

· Pharma & Health
₹ CrorePeersLASAMANGALAMBIOFILCHEMVINEETLABKREBSBIOALPABALPHARMANATCAPSUQMcap ₹10.1 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS-0.08-9.89-1.04-0.91-1.12
Diluted EPS-0.08-9.89-1.04-0.91-1.12
Book Value per Share13.363.472.431.521.52
Revenue per Share7.402.600.420.120.09
Cash Flow per Share-0.27-4.52-0.50-0.69—
Free Cash Flow per Share-0.27-4.52-0.51-0.69-0.69
Shares Outstanding (cr)0.80.80.80.80.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.